Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models.

Kuo, Chun-Ting; Chen, Chen-Lin; Li, Chih-Chi; Huang, Guan-Syuan; Ma, Wei-Yuan; Hsu, Wei-Fan; Lin, Ching-Hung; Lu, Yen-Shen; Wo, Andrew M

Kuo, Chun-Ting; Chen, Chen-Lin; Li, Chih-Chi; Huang, Guan-Syuan; Ma, Wei-Yuan; Hsu, Wei-Fan; Lin, Ching-Hung; Lu, Yen-Shen; Wo, Andrew M.

Afiliación

Kuo CT; Institute of Applied Mechanics, National Taiwan University, Taipei, 106, Taiwan.
Chen CL; Institute of Applied Mechanics, National Taiwan University, Taipei, 106, Taiwan.
Li CC; Institute of Applied Mechanics, National Taiwan University, Taipei, 106, Taiwan.
Huang GS; Institute of Applied Mechanics, National Taiwan University, Taipei, 106, Taiwan.
Ma WY; Institute of Applied Mechanics, National Taiwan University, Taipei, 106, Taiwan.
Hsu WF; Institute of Applied Mechanics, National Taiwan University, Taipei, 106, Taiwan.
Lin CH; Department of Oncology, National Taiwan University Hospital, Taipei, 100, Taiwan.
Lu YS; Department of Oncology, National Taiwan University Hospital, Taipei, 100, Taiwan. yslu@ntu.edu.tw.
Wo AM; Institute of Applied Mechanics, National Taiwan University, Taipei, 106, Taiwan. andrew@iam.ntu.edu.tw.

Sci Rep ; 10(1): 14139, 2020 Aug 19.

Article en En | MEDLINE | ID: mdl-32811854

ABSTRACT

ABSTRACT

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Taiwán